Abstract
Objective To investigate the genetic determinants of the most common type of antibody-mediated autoimmune encephalitis, anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis.
Methods We performed a genome-wide association study in 178 patients with anti-NMDAR encephalitis and 590 healthy controls followed by a colocalization analysis to identify putatively causal genes.
Results We identified two independent risk loci harboring genome-wide significant variants (P < 5 × 10−8, OR ≤ 2.2), one on chromosome 15, harboring only the LRRK1 gene, and one on chromosome 11 centered on the ACP2 and NR1H3 genes in a larger region of high linkage-disequilibrium. Colocalization signals with expression quantitative trait loci (eQTL) for different brain regions and immune cell types suggested ACP2, NR1H3, MADD, DDB2, and C11orf49 as putatively causal genes. The best candidate genes in each region are LRRK1, encoding Leucine-Rich Repeat Kinase 1, a protein involved in B-cell development, and NR1H3 liver x receptor alpha, a transcription factor whose activation inhibits inflammatory processes.
Conclusion This study provides evidence for relevant genetic determinants of antibody-mediated autoimmune encephalitides outside the HLA-region. The results suggest that future studies with larger sample sizes will successfully identify additional genetic determinants and contribute to the elucidation of the pathomechanism.
Competing Interest Statement
Klemens Angstwurm received travel support (2009-2014) from Alexion, BayerSchering, BiogenIdec, MerckSerono, Novartis, Teva. He further received honoraria for lectures (2009-present) from BiogenIdec, Berufsverband Deutscher Internisten BDI, Dt. Gesellschaft fuer Neuro-Intensiv- und Notfallmedizin DGNI, Dt. Gesellschaft fuer Neurologie DGN, Akademie fuer Infektionsmedizin, Aerztliche Kreisverbaende Cham und Cottbus and supported studies on neuroimmunological diseases by Alexion, BayerSchering, BiogenIdec, MerckSerono, Novartis, Roche. Frank Leypoldt reports speakers honoraria from Grifols, Alexion, Merck, Novartis, Roche, Fresenius, has served on advisory boards for Biogen, Roche and Alexion and works for an institution which offers commercial antibody testing. Markus Kraemer received honoriara for teaching activity from Roche Pharma and Cugai Pharma.
Funding Statement
This work is funded by the Federal Ministry of Education and Research (BMBF), Germany (funding code: 01GM1908A, project CONNECT-GENERATE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board approval was obtained from the ethical advisory boards of the Universities of Kiel and Luebeck (B337/13;13-162).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary level genetic data for all variants with P-values < 1e-04 are available from the corresponding author on reasonable request to any qualified investigator.
